At LenioBio GmbH, everything we do begins with our mission - to provide our customers with disruptive solutions to address their challenges easier, quicker, cheaper, better and safer.

LenioBio is a biotech company that develops and markets a novel and proprietary protein production platform, ALiCE®, which enables protein-based therapeutics to become more accessible and affordable. LenioBio was founded in 2016 in Germany to broadly commercialize the ALiCE® platform, originally developed by DowDuPont and the Fraunhofer Institute IME.

In August 2019, LenioBio closed its Series A investment round with private investors, and won a grant from the European Commission under the Horizon 2020 program/SME-2.

At LenioBio, we believe in the power of simplicity. It is our purpose to deliver better access to complex proteins.

LenioBio is developing the ALiCE® technology into the first scalable eukaryotic cell-free production platform for proteins. ALICE® scales with the pharmaceutical R&D process, from discovery to clinical trials/product testing and finally, to GMP-grade production, in the form of an end-to-end integrated production platform.